Nasdaq-Traded Greenbrook Takes A Leap Into The Psychedelics Medicine Space Greenbrook TMS, a Nasdaq-traded provider of Transcranial Magnetic Stimulation (TMS) therapy for the treatment of Major Depressive Disorder and Obsessive Compulsive Disorder valued at roughly $200 million, is taking a leap into the psychedelics world.